Sasa Semeredi1, Valdemar Stajer1, Jelena Ostojic2, Milan Vranes3, Sergej M Ostojic4. 1. Faculty of Sport and Physical Education, University of Novi Sad, Novi Sad, Serbia. 2. Faculty of Medicine, University of Southern Denmark, Ostende, Denmark. 3. Faculty of Sciences, University of Novi Sad, Novi Sad, Serbia. 4. Faculty of Sport and Physical Education, University of Novi Sad, Novi Sad, Serbia; University of Belgrade School of Medicine, Belgrade, Serbia. Electronic address: Sergej.ostojic@chess.edu.rs.
Abstract
PURPOSE: Co-administration of creatine and guanidinoacetic acid (GAA) has been recently put forward as an advanced dietary strategy to optimize tissue bioenergetics. We hypothesized that creatine-GAA mixture would result in a more powerful rise in brain and skeletal muscle creatine, as compared to creatine supplementation alone. METHODS: A randomized, double-blinded, crossover superiority trial has been performed at the University of Novi Sad from December 2016 to November 2017. A total of 14 healthy young men were randomized to receive GAA-creatine mixture (1 grams of GAA and 3 grams of creatine per day) or equimolar creatine (4 grams per day) by oral administration for 4 weeks. RESULTS:Creatine-GAA mixture was superior to creatine alone to increase mean creatine levels in skeletal muscle (16.9 ± 20.2 vs. 2.0 ± 6.0%; P = 0.02) and grey matter (5.8 ± 5.3% vs. 1.5 ± 3.2%; P = 0.02), also for bench press performance (6.0% vs. 5.1%; P < 0.01). Compared with creatine administration alone, combined GAA and creatine resulted in less weight gain (1.6 ± 0.2 kg vs. 0.7 ± 0.2 kg; P < 0.01). No inter-group differences were observed in terms of cardiorespiratory endurance, serum biomarkers, or adverse events. CONCLUSIONS:Creatine-GAA mixture appeared to be superior to creatine alone for up-swinging tissue creatine content and upper body strength, and tended toward a lower risk of weight gain in healthy active men. The formulation might be considered as a novel energy-boosting alternative to creatine alone in weight-sensitive setups. TRIAL REGISTRATION: ClinicalTrials.govNCT03350282.
RCT Entities:
PURPOSE: Co-administration of creatine and guanidinoacetic acid (GAA) has been recently put forward as an advanced dietary strategy to optimize tissue bioenergetics. We hypothesized that creatine-GAA mixture would result in a more powerful rise in brain and skeletal muscle creatine, as compared to creatine supplementation alone. METHODS: A randomized, double-blinded, crossover superiority trial has been performed at the University of Novi Sad from December 2016 to November 2017. A total of 14 healthy young men were randomized to receive GAA-creatine mixture (1 grams of GAA and 3 grams of creatine per day) or equimolar creatine (4 grams per day) by oral administration for 4 weeks. RESULTS:Creatine-GAA mixture was superior to creatine alone to increase mean creatine levels in skeletal muscle (16.9 ± 20.2 vs. 2.0 ± 6.0%; P = 0.02) and grey matter (5.8 ± 5.3% vs. 1.5 ± 3.2%; P = 0.02), also for bench press performance (6.0% vs. 5.1%; P < 0.01). Compared with creatine administration alone, combined GAA and creatine resulted in less weight gain (1.6 ± 0.2 kg vs. 0.7 ± 0.2 kg; P < 0.01). No inter-group differences were observed in terms of cardiorespiratory endurance, serum biomarkers, or adverse events. CONCLUSIONS:Creatine-GAA mixture appeared to be superior to creatine alone for up-swinging tissue creatine content and upper body strength, and tended toward a lower risk of weight gain in healthy active men. The formulation might be considered as a novel energy-boosting alternative to creatine alone in weight-sensitive setups. TRIAL REGISTRATION: ClinicalTrials.govNCT03350282.
Authors: Scott C Forbes; Dean M Cordingley; Stephen M Cornish; Bruno Gualano; Hamilton Roschel; Sergej M Ostojic; Eric S Rawson; Brian D Roy; Konstantinos Prokopidis; Panagiotis Giannos; Darren G Candow Journal: Nutrients Date: 2022-02-22 Impact factor: 5.717
Authors: Sergej M Ostojic; Jelena Ostojic; Dragana Zanini; Tatjana Jezdimirovic; Valdemar Stajer Journal: J Int Med Res Date: 2022-01 Impact factor: 1.671